Precision Medicine Mrna Design (Grade A)Security-tested data-ai skill for Claude AI. Grade A. Comprehensive precision medicine framework for veterinary cancer therapy including mRNA neoantigen vaccine design, pharmacogenomics, targeted ther

Comprehensive precision medicine framework for veterinary cancer therapy including mRNA neoantigen vaccine design, pharmacogenomics, targeted therapy, and companion diagnostics. Bridges genomics and personalized treatment. Precision Medicine & mRNA Design Overview Precision veterinary medicine tailors cancer therapy to individual tumor genetics and patient pharmacogenomics. This skill covers three pillars: (1) mRNA neoantigen vaccine design for personalized immunotherapy, (2) pharmacogenomics for optimal drug dosing and efficacy prediction, and (3) companion diagnostics linking genetic markers to therapeutic response. Real-world example: rescue dog "Rosie" with aggressive mast cell cancer treated with personalized mRNA vaccine. When to Use User designs personalized neoantigen mRNA vaccine for canine/feline cancer patient User interprets tumor genomic sequencing (somatic mutations, tumor mutational burden) for treatment selection User predicts drug response/toxicity based on pharmacogenomic variants (MDR1, CYP450) User selects targeted therapy matching tumor driver mutations (BRAF, KIT, TP53) User understands mRNA construct design (5' cap, ORF, poly-A tail, delivery logistics) Keywords: precision medicine, mRNA vaccine, neoantigen, pharmacogenomics, targeted therapy, companion diagnostics, personalized immunotherapy Related skill: For the detailed 8-step neoantigen vaccine pipeline (sequencing, variant calling, DLA typing, prediction, synthesis), see neoantigen-vaccine-design. This skill covers the broader precision medicine framework; that skill covers the specific mRNA vaccine bioinformatics workflow. The Precision Medicine Framework Three Pillars of Personalization: ┌─────────────────────────────────────┐ │ PRECISION VETERINARY MEDICINE │ ├─────────────────────────────────────┤ │ │ │ 1. MRNA NEOANTIGEN VACCINES │ │ └─ Tumor sequencing │ │ └─ Neoantigen prediction │ │ └─ mRNA synthesis │ │ └─ Immunotherapy │ │ │ │ 2. PHARMACOGENOMICS │ │ └─ Patient germline variants │ │ └─ Drug metabolism prediction │ │ └─ Dosing optimization │ │ └─ Toxicity prediction │ │ │ │ 3. COMPANION DIAGNOSTICS │ │ └─ Tumor driver mutations │ │ └─ Predictive biomarkers │ │ └─ Therapy selection │ │ └─ Prognosis assessment │ │ │ └─────────────────────────────────────┘ Pillar 1: mRNA Neoantigen Vaccine Design What is a Neoantigen? Definition: Tumor-specific mutation that creates a novel protein epitope not present in normal tissue. Neoantigens are immunogenic (unlike wild-type self-antigens); vaccines targeting neoantigens activate tumor-destroying CD8+ T cells without autoimmunity risk. Example: TP53 Mutation in Canine Osteosarcoma Wild-type TP53 sequence (normal cell): MPPQPQ...SVQLG... (normal p53 protein) Tumor TP53 mutation (R175H): MPPQPQ...SHHQG... (mutant p53 protein - neoantigen!) Neoantigen epitope (8-10 amino acid segment): ...HHQG... differs from wild-type; recognized as foreign by immune system mRNA vaccine presents this epitope CD8+ T cells attack tumor cells expressing R175H Workflow: Tumor Sequencing to mRNA Vaccine Step 1: Tumor Tissue Collection & Sequencing Surgical biopsy: Fresh tumor sample (optimal) or archived tissue DNA extraction: Isolate tumor cell DNA Matched normal tissue: Peripheral blood or normal tissue (distinguish somatic vs. germline mutations) Seq